Regulation of glial lineage by Olig2

Olig2 对神经胶质谱系的调节

基本信息

  • 批准号:
    8144885
  • 负责人:
  • 金额:
    $ 22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-15 至 2012-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Glial cells in the mammalian central nervous system (CNS) that express the NG2 proteoglycan (NG2 cells) appear during late embryonic stages and rapidly expand to uniformly occupy the entire CNS. These cells are distinct from mature oligodendrocytes, astrocytes, or resting ramified microglia and represent a fourth major glial population. Cultured NG2 cells give rise to oligodendrocytes and are thus called oligodendrocyte precursor cells (OPCs). In vivo fate mapping studies using our newly generated NG2creBAC transgenic mice revealed that NG2 cells in the white matter and dorsal forebrain generate exclusively oligodendrocytes, while those in the gray matter of the ventral forebrain generate both oligodendrocytes and protoplasmic astrocytes. When the basic helix-loop-helix transcription factor Olig2 is deleted in NG2 cells, almost all the NG2 cells in the dorsal forebrain differentiate into astrocytes at the expense of oligodendrocytes, resulting in myelin loss. Thus, NG2 cells retain lineage plasticity, and a single transcription factor Olig2 plays a critical role in maintaining the oligodendroglial fate of NG2 cells. Deletion of Olig2 in more differentiated oligodendrocytes does not alter the level of neocortical GFAP expression, in contrast to Olig2 deletion at earlier stages, suggesting that there is a developmental window in which oligodendrocyte lineage cells can be converted into astrocytes in the absence of Olig2. Aim 1 will test the hypothesis that NG2 cells lose their lineage plasticity and become incapable of generating astrocytes as they mature into oligodendrocytes, and that restriction of lineage plasticity in NG2 cells is regulated by epigenetic mechanisms. Aim 2 will test the hypothesis that there is a signaling pathway that maintains the expression of Olig2 in NG2 cells in the normal brain and prevents them from differentiating into astrocytes. This will be explored by screening small-molecule libraries for a compound that alters Olig2 transcriptional activity. Identified compounds will be used in future studies to delineate the endogenous signaling pathways that regulate Olig2 expression. The pathway could then be manipulated in future injury repair paradigms to promote differentiation of NG2 cells into the desired cell type. PUBLIC HEALTH RELEVANCE: NG2 cells represent a glial progenitor population that is ubiquitously distributed throughout the gray and white matter of the central nervous system. The proposed studies are aimed to identify the mechanisms that regulate their lineage plasticity through the transcription factor Olig2. The results from these studies can be used in future experiments in which the fate of endogenous NG2 cells can be manipulated to maximize their contribution to lesion repair in various types injury.
描述(由申请人提供):哺乳动物中枢神经系统(CNS)中表达NG2蛋白聚糖(NG2细胞)的胶质细胞在胚胎后期出现,并迅速扩张并均匀地占据整个中枢神经系统。这些细胞不同于成熟的少突胶质细胞、星形胶质细胞或静止的分枝小胶质细胞,它们代表了第四种主要的胶质细胞群。培养的NG2细胞产生少突胶质细胞,因此被称为少突胶质细胞前体细胞(OPCs)。利用NG2creBAC转基因小鼠进行的体内命运图谱研究显示,NG2细胞在白质和前脑背侧只产生少突胶质细胞,而在前脑腹侧灰质中既产生少突胶质细胞,也产生原生质星形胶质细胞。当NG2细胞中基本的螺旋-环-螺旋转录因子Olig2缺失时,前脑背侧的NG2细胞几乎全部以少突胶质细胞为代价分化为星形胶质细胞,导致髓磷脂损失。因此,NG2细胞保持谱系可塑性,单一转录因子Olig2在维持NG2细胞的少突胶质命运中起着关键作用。在分化程度较高的少突胶质细胞中,Olig2缺失不会改变新皮质GFAP的表达水平,这与早期阶段的Olig2缺失不同,这表明在缺乏Olig2的情况下,少突胶质细胞谱系细胞可以转化为星形胶质细胞。目的1将验证NG2细胞在向少突胶质细胞成熟的过程中失去谱系可塑性并不能产生星形胶质细胞的假设,以及NG2细胞谱系可塑性的限制受到表观遗传机制的调节。Aim 2将验证一个假设,即存在一种信号通路维持正常大脑NG2细胞中Olig2的表达,并阻止其分化为星形胶质细胞。这将通过筛选小分子文库来探索改变Olig2转录活性的化合物。鉴定的化合物将在未来的研究中用于描述调节Olig2表达的内源性信号通路。然后,在未来的损伤修复范式中,可以操纵该途径,以促进NG2细胞分化为所需的细胞类型。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Akiko Nishiyama其他文献

Akiko Nishiyama的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Akiko Nishiyama', 18)}}的其他基金

SNARE complex-mediated exocytosis in oligodendrocyte differentiation and survival
SNARE 复合物介导的少突胶质细胞分化和存活中的胞吐作用
  • 批准号:
    10117297
  • 财政年份:
    2020
  • 资助金额:
    $ 22万
  • 项目类别:
SNARE complex-mediated exocytosis in oligodendrocyte differentiation and survival
SNARE 复合物介导的少突胶质细胞分化和存活中的胞吐作用
  • 批准号:
    10598491
  • 财政年份:
    2020
  • 资助金额:
    $ 22万
  • 项目类别:
SNARE complex-mediated exocytosis in oligodendrocyte differentiation and survival
SNARE 复合物介导的少突胶质细胞分化和存活中的胞吐作用
  • 批准号:
    10377531
  • 财政年份:
    2020
  • 资助金额:
    $ 22万
  • 项目类别:
Leica TCS SP8 FSU AOBS 405 UV Spectral Confocal Microscope
Leica TCS SP8 FSU AOBS 405 紫外光谱共焦显微镜
  • 批准号:
    8640318
  • 财政年份:
    2014
  • 资助金额:
    $ 22万
  • 项目类别:
Heterogeneity of NG2 Glial Cells
NG2 胶质细胞的异质性
  • 批准号:
    8662817
  • 财政年份:
    2012
  • 资助金额:
    $ 22万
  • 项目类别:
Heterogeneity of NG2 Glial Cells
NG2 胶质细胞的异质性
  • 批准号:
    8439659
  • 财政年份:
    2012
  • 资助金额:
    $ 22万
  • 项目类别:
Heterogeneity of NG2 Glial Cells
NG2 胶质细胞的异质性
  • 批准号:
    8845621
  • 财政年份:
    2012
  • 资助金额:
    $ 22万
  • 项目类别:
Heterogeneity of NG2 Glial Cells
NG2 胶质细胞的异质性
  • 批准号:
    8531362
  • 财政年份:
    2012
  • 资助金额:
    $ 22万
  • 项目类别:
Inflammation and NG2 Cell Differentiation
炎症和 NG2 细胞分化
  • 批准号:
    8187904
  • 财政年份:
    2011
  • 资助金额:
    $ 22万
  • 项目类别:
Inflammation and NG2 Cell Differentiation
炎症和 NG2 细胞分化
  • 批准号:
    8662815
  • 财政年份:
    2011
  • 资助金额:
    $ 22万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22万
  • 项目类别:
    Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 22万
  • 项目类别:
    Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 22万
  • 项目类别:
    Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 22万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 22万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 22万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 22万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 22万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 22万
  • 项目类别:
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 22万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了